Almirall S.A. announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study, which resembled real-life clinical practice. In this study, Ilumetri® (tildrakizumab) is the first IL-23p19 inhibitor to demonstrate improvement on sleep impairment in patients with moderate-to-severe chronic plaque psoriasis. At week 24, the MOS-Sleep (Medical Outcomes Study-Sleep) index II showed a statistically significant and clinically relevant benefit, with a score close to population norm.

Moreover, after 24 weeks of treatment with tildrakizumab, 76,5% and 84,9% of patients reported mild itch and pain, respectively. Significant improvement in scaling was also demonstrated in the TRIBUTE study. These benefits on burdensome symptoms were accompanied by high levels of treatment satisfaction, and 70,4% of patients had no impairment on health-related quality of life.

TRIBUTE once again confirms the effectiveness of tildrakizumab with two thirds of patients achieving a psoriasis area and severity score of less than 1 after 24 weeks. Finally, tildrakizumab demonstrated a favourable safety profile similar to that seen in phase III trials. Approximately 60 million people live with psoriasis worldwide.

This skin condition disrupts every aspect of patients' daily lives: from sleep, clothing choices, and exercise, to work and social life, preventing them from the possibility of leading a normal daily life. Although 88% of the patients affirm that the condition affects their overall emotional wellbeing, the impact of psoriasis on physical, social, and psychological wellbeing is often underestimated. Almirall presented 12 tildrakizumab posters at the 31st EADV Congress.

In addition to TRIBUTE, the company showcased long-term data from the large, non-interventional, prospective TILOT study. Tildrakizumab demonstrated significant and sustained efficacy, high treatment satisfaction and a favourable safety profile in a real-world setting12 with similar results in both bio-experienced and bio-naïve patients. Pooled analyses from the Phase 3 trials reSURFACE 1 and reSURFACE 2 over 5 years, also presented in the congress, indicate that tildrakizumab provides long-term disease control across a wide range of patient characteristics (e.g. previous biological therapy, type 2 diabetes and psychiatric disorders).